Parkworth Wealth Management’s Vaxcyte PCVX Stock Holding History

Parkworth Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$260	Buy	+8	New	+$262	﹤0.01%	856

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Parkworth Wealth Management's PCVX Position: Q2 2025 in Review

Parkworth Wealth Management opened a new position in Vaxcyte (PCVX) in Q2 2025: 8 shares worth $260. The stake represents ﹤0.01% of the portfolio and ranks #856 among its holdings.

294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Parkworth Wealth Management held 8 shares of Vaxcyte worth $260 as of Q2 2025.
Vaxcyte was a new Parkworth Wealth Management position in Q2 2025.
Vaxcyte made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #856 holding.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.